NEW YORK (GenomeWeb) – Natera and Illumina have extended and expanded their supply agreement, through which Natera purchases Illumina's products, until June 8, 2026, according to a document filed this week with the US Securities and Exchange Commission.
In addition, the companies expanded the agreement, granting Natera the rights to use Illumina's products for oncology and transplant diagnostic testing in Natera's CLIA certified laboratory. In addition, Natera has the rights to develop and sell oncology IVD products and services worldwide based on Illumina's technology, in exchange for milestone payments to Illumina and royalties from the sale of IVDs.
Natera also said it is pursuing a premarket approval from the US Food and Drug Administration for at least one IVD. If Natera has not obtained the PMA by June 8, 2021 and is not "diligently pursuing an active PMA" at that time, Illumina has the right to terminate the agreement upon two years notice.
Separately, Natera elected two directors to serve on its board — James Healy and Edward Driscoll.